HALOZYME THERAPEUTICS, INC. SAN DIEGO, March 22, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the nomination of Jean-Pierre Bizzari, M.D. and James M. Daly as Class II directors for reelection at the Company's 2018 stockholder meeting. Following communication by Randal J. Kirk of his unavailability for further service due to growing commitments outside Halozyme, it has been agreed that Mr. Kirk will not be nominated for reelection to the board of directors.
Mr. Kirk joined the board of directors nearly 11 years ago at a formative time for the company and remains Halozyme's largest shareholder.
"I will leave the Halozyme board with the company in its strongest position in history by any objective measure, be it financial, strategic or operational," said Mr. Kirk. "I am very pleased with the progress Helen and her management team have made in substantially increasing the value of the firm and intend to retain my ownership position. With the foundation in place for continued growth at Halozyme, I feel confident in its continued success."
Mr. Kirk will serve out his term through the company's annual meeting of stockholders on May 2.
"R.J. has been a steadfast and valued adviser since he and the board hired me in 2014," said Helen Torley, president, CEO and member of the board of directors. "I am thankful for his support of Halozyme's transition to our value-creating, two-pillar strategy. With his counsel we are in a strong position today, with an experienced board and management team in place to execute our strategy."
Board Chair Connie L. Matsui said, "R.J. has been an exemplary board member and colleague for over a decade. The board is deeply grateful for his service."
The board's Nominating and Governance Committee will lead the search for a new board member.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, and gastric cancer, and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the Company's future expectations and plans for growth in 2018, entering into new collaboration agreements, the development and commercialization of product candidates, including timing of clinical trial results announcements and future development and commercial activities of our collaboration partners, the potential benefits and attributes of such product candidates and expected financial outlook for 2018) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected fluctuations or changes in revenues, including revenues from collaborators, unexpected delays in entering into new collaboration agreements, unexpected results or delays in development of product candidates, including delays in clinical trial patient enrollment and development activities of our collaboration partners, and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 20, 2018.
Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
View original content with multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-nomination-of-directors-for-reelection-at-2018-stockholder-meeting-300618304.html
SOURCE Halozyme Therapeutics, Inc.
